字号·· | 护眼
商业内幕

德勤将取消美国员工减肥用途GLP-1药物承保,并上调医疗保险费用Deloitte is cutting GLP-1 coverage for weight loss and raising health insurance costs for US staff

点「原文对照」整页切到原文,或双击某段只看那段的原文。

德勤美国员工加入了面临医疗福利更昂贵、慷慨程度降低的工人不断增长的行列。据《商业内幕》看到的一份内部福利指南显示,从1月开始,这家四大公司之一将不再通过其医疗计划覆盖用于减重目的的GLP-1药物。同时,该文件称,德勤员工在大多数健康计划下还将面临更高的免赔额和自付费用上限,这意味着在保险生效前后成本都会增加。

Deloitte's US employees are joining the growing list of workers facing more expensive and less generous healthcare benefits. According to an internal benefits guide seen by Business Insider, from January, the Big Four firm will no longer cover GLP-1 medication for weight-loss purposes through its medical plans. At the same time, Deloitte employees will also face higher deductibles and out-of-pocket maximums under most health plans, the document said, meaning higher costs both before and after coverage kicks in.

这些变化出台之际,美国企业界正在应对员工和雇主健康保险成本普遍上涨的问题。德勤在文件中告诉员工,这些变化“反映了当今成本环境下的艰难权衡”,并且“在少数几个德勤独自承担成本已变得不可持续的具体领域,需要共同承担责任”。文件称,当GLP-1药物被处方用于糖尿病和其他覆盖的医疗状况时,将继续获得覆盖。

The changes come as corporate America battles a widespread rise in health insurance costs for both employees and employers. Deloitte told staff in the document that the changes "reflect the hard trade-offs of today's cost environment," and that there was a need "for shared responsibility in a few specific places where it's become untenable for Deloitte to carry the cost alone." GLP-1 medication will remain covered when prescribed for diabetes and other covered medical conditions, the document said.

对于寻求减重支持的员工,德勤转而提供一个名为eMed的虚拟生活方式项目,该项目包含指导服务以及每张处方125美元的雇主资助。司美格鲁肽和替尔泊肽等常见GLP-1药物的标价通常超过1000美元,尽管礼来直购等厂家直销计划以及TrumpRx等政府计划意味着成本通常显著更低。例如,TrumpRx以Ozempic品牌名提供司美格鲁肽注射笔,价格在199美元至499美元之间。

For those seeking support with weight loss, Deloitte is instead offering employees access to a virtual lifestyle program called eMed that includes coaching and a $125-per-prescription employer contribution. List prices for common GLP-1s like semaglutide and tirzepatide are generally in excess of $1,000, though direct purchase programs such as LillyDirect and government plans like TrumpRx mean the costs are often significantly lower. TrumpRx, for instance, offers semaglutide injection pens under the Ozempic brand name for between $199 and $499.

德勤发言人告诉《商业内幕》,与其他大型雇主一样,该公司在成本增长率不再可持续的地方进行了精选调整。针对GLP-1药物用于体重相关用途的新支持包括厂家直供药价一台非工作设备;

A Deloitte spokesperson told Business Insider that, like other large employers, the firm has made select modifications where cost growth rates are no longer sustainable. The new support for weight-related uses of GLP-1s includes direct-from-manufacturer drug pricing a nonwork device; here's our guide to sharing information securely.

德勤还在扩大部分医疗保障范围,包括改善长期残疾保障,并将免费年度眼科检查纳入公司承担费用的折扣视力保健计划。《商业内幕》看到的福利指南适用于德勤所谓的“核心、领域和企业专业人员”,这包括其大多数传统面向客户的会计师、顾问和技术专家。该公司在美国雇佣约18.1万人。德勤对其保障范围的调整反映了美国雇主健康计划面临的更广泛挤压。

Deloitte is also expanding certain healthcare coverage, including improving long-term disability protection and adding free annual eye exams to its company-paid discount vision program. The benefits guide seen by Business Insider applies to what Deloitte calls its "Core, Domain, and Enterprise professionals," which includes the majority of its traditional client-facing accountants, consultants, and technical specialists. The firm employs about 181,000 people in the US. Deloitte's changes to its coverage mirror a broader squeeze on US employer health plans.

随着医疗成本和需求攀升,每个人支付的费用都在增加。KFF 2026年健康福利调查发现,参加家庭计划的员工每年平均支付7471美元保费——较2025年增长9%。加上雇主缴纳部分后,家庭计划保费总额在2026年达到28303美元,较2025年增长约5%。

As healthcare costs and demand climb, everyone is paying more. A 2026 health benefits survey from KFF found that workers on a family plan paid an average of $7,471 a year in premiums — a 9% increase from 2025. When accounting for employer contributions, family plan premiums totaled $28,303 in 2026, a roughly 5% increase from 2025.

限制GLP-1类药物的适用资格,已成为雇主遏制医疗支出的常见途径。这类药物原本是为治疗糖尿病而开发,但已成为治疗肥胖及相关慢性病的热门药物。保险经纪和员工福利咨询公司Aon发现,2025年GLP-1类药物的使用量激增75%。这些药物的快速普及和潜在的长期使用,使其成为保险公司和雇主健康计划的一个高昂压力点。Aon发现,39%的雇主计划在2026年减少或限制GLP-1类药物保障。普华永道和星巴克是今年收回减重用途保障的雇主之一。

Restricting eligibility for GLP-1s has become a common route for employers looking to curb healthcare spending. The drugs were developed to treat diabetes, but have become sought-after treatments for obesity and related chronic conditions. Aon, an insurance broker and employee-benefits consultancy, found that use of GLP-1s was up 75% in 2025. The drugs' rapid uptake and potential for long-term use have made them a costly pressure point for insurers and employer health plans. Aon found that 39% of employers planned to reduce or restrict GLP-1 coverage in 2026. PwC and Starbucks are among those that have pulled back their coverage for weight-loss purposes this year.

德勤还为部分员工推出了更广泛的福利变动。据《商业内幕》4月报道,对于德勤“中心”人才模式下的员工——主要包括内部面向的行政岗位——产假、年假和试管婴儿资助将从2027年1月1日起减少或取消。

Deloitte has also introduced broader benefit changes for a select group of staff. In April, Business Insider reported that for staff in Deloitte's Center talent model — which mostly includes internal-facing admin roles — parental leave, annual PTO, and IVF funding would be reduced or eliminated as of January 1, 2027.

截至2026年5月31日的财年中,德勤美洲分部是其全球增长最慢的地区,收入增长3.2%,低于上一年的7.1%增速。

Deloitte's Americas division was its slowest-growing region globally in the financial year ending May 31, 2026, with revenue rising 3.2%, down from 7.1% growth a year earlier.

阅读媒体原文 ↗